Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc
("Summit" or the "Company")

EXERCISE OF OPTIONS

Oxford, UK, 24 March 2015 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that on 23 March 2015 it received a notification of exercise in respect of options granted over 16,777 new ordinary shares in the Company at an exercise price of 65 pence per share and 10,607 new ordinary shares in the Company at an exercise price of 20 pence per share.  Consequently the Company has issued and allotted 27,384 new ordinary shares in the Company. 

An application has been made for the 27,384 new ordinary shares to be admitted to AIM and admission is expected to occur on or around 27 March 2015.  Following this issue of equity above the Company's issued share capital will comprise of 60,982,581 ordinary shares of 1 penny each.

- END -

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection.

For more information, please contact: